Molecular imaging phenotyping for selecting and monitoring radioligand therapy of neuroendocrine neoplasms.
Molecular imaging
Neuroendocrine tumours
Peptide receptor radionuclide therapy
Positron emission tomography
Radioligand therapy
Somatostatin receptor
Journal
Cancer imaging : the official publication of the International Cancer Imaging Society
ISSN: 1470-7330
Titre abrégé: Cancer Imaging
Pays: England
ID NLM: 101172931
Informations de publication
Date de publication:
03 Jun 2022
03 Jun 2022
Historique:
received:
22
12
2021
accepted:
26
05
2022
entrez:
6
6
2022
pubmed:
7
6
2022
medline:
9
6
2022
Statut:
epublish
Résumé
Neuroendocrine neoplasia (NEN) is an umbrella term that includes a widely heterogeneous disease group including well-differentiated neuroendocrine tumours (NETs), and aggressive neuroendocrine carcinomas (NECs). The site of origin of the NENs is linked to the intrinsic tumour biology and is predictive of the disease course. It is understood that NENs demonstrate significant biologic heterogeneity which ultimately translates to widely varying clinical presentations, disease course and prognosis. Thus, significant emphasis is laid on the pre-therapy evaluation of markers that can help predict tumour behavior and dynamically monitors the response during and after treatment. Most well-differentiated NENs express somatostatin receptors (SSTRs) which make them appropriate for peptide receptor radionuclide therapy (PRRT). However, the treatment outcomes of PRRT depend heavily on the adequacy of patient selection by molecular imaging phenotyping not only utilizing pre-treatment SSTR PET but
Identifiants
pubmed: 35659779
doi: 10.1186/s40644-022-00465-3
pii: 10.1186/s40644-022-00465-3
pmc: PMC9164531
doi:
Substances chimiques
Receptors, Somatostatin
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
25Informations de copyright
© 2022. The Author(s).
Références
J Nucl Med. 2010 Sep;51(9):1349-56
pubmed: 20720050
Ann Nucl Med. 2012 May;26(4):365-9
pubmed: 22361935
Head Neck. 2020 Mar;42(3):401-416
pubmed: 31755622
Eur J Nucl Med Mol Imaging. 2015 Jan;42(1):25-32
pubmed: 25125202
J Nucl Med. 2009 Dec;50(12):1927-32
pubmed: 19910422
J Nucl Med. 2019 Jul;60(7):1010-1016
pubmed: 30530828
Endocr Relat Cancer. 2018 Oct 1;26(2):131-146
pubmed: 30400059
Eur J Nucl Med Mol Imaging. 2018 Sep;45(10):1836-1837
pubmed: 29713764
Endocr Relat Cancer. 2020 Mar;27(3):R67-R77
pubmed: 31846429
Eur J Nucl Med Mol Imaging. 2016 Jun;43(6):1040-6
pubmed: 26611427
J Nucl Med. 2014 Nov;55(11):1786-90
pubmed: 25286923
Ital J Gastroenterol Hepatol. 1999 Oct;31 Suppl 2:S219-23
pubmed: 10604135
Endocr Relat Cancer. 2012 Feb 13;19(1):83-93
pubmed: 22167067
Am J Surg Pathol. 2014 Jun;38(6):756-67
pubmed: 24705311
Ann Oncol. 2013 Jan;24(1):152-60
pubmed: 22967994
J Nucl Med. 2021 Oct;62(10):1406-1414
pubmed: 33579805
J Clin Endocrinol Metab. 2012 Feb;97(2):482-8
pubmed: 22112810
Endocr Relat Cancer. 2019 Nov;26(11):R627-R652
pubmed: 31561209
Eur J Nucl Med. 2000 Mar;27(3):273-82
pubmed: 10774879
J Nucl Med. 2022 Feb;63(2):310-315
pubmed: 34215672
Am J Nucl Med Mol Imaging. 2013 Dec 15;4(1):39-52
pubmed: 24380044
Oncotarget. 2020 Feb 11;11(6):589-599
pubmed: 32110279
J Nucl Med. 2021 Aug 1;62(8):1033-1042
pubmed: 34330739
Thyroid. 2020 Apr;30(4):557-567
pubmed: 31870227
J Nucl Med. 2005 Jan;46 Suppl 1:107S-14S
pubmed: 15653659
Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):2112-2137
pubmed: 31254038
J Nucl Med. 2010 Jul;51(7):1059-67
pubmed: 20595511
Crit Rev Oncol Hematol. 2009 Sep;71(3):199-213
pubmed: 19362010
Prostate. 2014 Aug;74(11):1153-9
pubmed: 24913988
Oncotarget. 2017 Jan 24;8(4):7039-7049
pubmed: 27705948
Eur J Nucl Med Mol Imaging. 2020 Apr;47(4):881-894
pubmed: 31414209
AJR Am J Roentgenol. 2022 May;218(5):767-780
pubmed: 34985313
J Nucl Med. 2007 May;48(5):736-43
pubmed: 17475961
J Thorac Oncol. 2020 Oct;15(10):1577-1598
pubmed: 32663527
Eur J Nucl Med Mol Imaging. 2021 Sep;48(10):3260-3267
pubmed: 33604690
CA Cancer J Clin. 2018 Nov;68(6):471-487
pubmed: 30295930
Clin Nucl Med. 2018 Aug;43(8):e285-e286
pubmed: 29877881
J Nucl Med. 2014 Jun;55(6):976-82
pubmed: 24744444
Sci Rep. 2018 Feb 13;8(1):2948
pubmed: 29440684
Clin Cancer Res. 2021 Jun 1;27(11):2989-2995
pubmed: 33685867
J Nucl Med. 2021 Oct;62(10):1323-1329
pubmed: 34301785
Clin Cancer Res. 2015 Sep 1;21(17):3888-95
pubmed: 25873086
Eur J Nucl Med Mol Imaging. 2021 Jan;48(1):204-216
pubmed: 32572559
Endocr Relat Cancer. 2020 Apr;27(4):R79-R92
pubmed: 31951592
Eur J Nucl Med Mol Imaging. 2010 Dec;37(12):2436-46
pubmed: 20644928
Eur J Nucl Med Mol Imaging. 2014 Oct;41(10):1831-44
pubmed: 24844348
J Nucl Med. 2017 Jan;58(1):91-96
pubmed: 27516446
Cancer Imaging. 2020 Aug 10;20(1):57
pubmed: 32778165
Mol Cell Endocrinol. 2012 Feb 26;349(2):170-9
pubmed: 22040601
Pancreas. 2014 Jul;43(5):675-86
pubmed: 24921202
Am J Clin Exp Urol. 2014 Dec 09;2(4):273-85
pubmed: 25606573
J Nucl Med. 2020 Jun;61(6):897-903
pubmed: 31676731
Pol Arch Intern Med. 2018 Dec 21;128(12):791-795
pubmed: 30516761
J Nucl Med. 2017 Sep;58(Suppl 2):10S-16S
pubmed: 28864606
Clin Cancer Res. 2010 Feb 1;16(3):978-85
pubmed: 20103666
J Nucl Med. 2021 Nov;62(11):1571-1581
pubmed: 33674401
J Nucl Med. 2018 Jan;59(1):66-74
pubmed: 29025982
Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6696-702
pubmed: 18006770
J Clin Endocrinol Metab. 2007 Oct;92(10):3822-8
pubmed: 17652212
J Nucl Med. 2019 May;60(5):623-630
pubmed: 30291194
J Nucl Med. 2011 Dec;52(12):1855-63
pubmed: 22052128
J Clin Oncol. 2009 Sep 1;27(25):4162-8
pubmed: 19636009
N Engl J Med. 2017 Jan 12;376(2):125-135
pubmed: 28076709
Intern Med J. 2021 Oct;51(10):1657-1664
pubmed: 33314504
J Nucl Med. 2015 Apr;56(4):613-5
pubmed: 25698785
J Nucl Med. 2022 Mar;63(3):396-398
pubmed: 34475234
Clin Nucl Med. 2017 Jan;42(1):1-6
pubmed: 27775942
Clin Genitourin Cancer. 2021 Aug;19(4):e200-e205
pubmed: 33678552
J Immunother Cancer. 2020 Jul;8(2):
pubmed: 32616557
Neuroendocrinology. 2015;101(3):223-35
pubmed: 25765179
Pathol Res Pract. 2012 Aug 15;208(8):470-4
pubmed: 22770972
Clin Nucl Med. 2019 Nov;44(11):876-878
pubmed: 31584494
J Nucl Med. 2009 Sep;50(9):1427-34
pubmed: 19690033
Semin Nucl Med. 2012 May;42(3):190-207
pubmed: 22475428
N Engl J Med. 2019 Aug 8;381(6):552-565
pubmed: 31390501
Eur J Nucl Med Mol Imaging. 2016 Aug;43(9):1585-92
pubmed: 26922350
Best Pract Res Clin Gastroenterol. 2005 Oct;19(5):783-98
pubmed: 16253900
N Engl J Med. 2014 Jul 17;371(3):224-33
pubmed: 25014687
Cancer Imaging. 2016 Aug 17;16(1):22
pubmed: 27535829
Theranostics. 2020 Jan 1;10(1):437-461
pubmed: 31903131
J Nucl Med. 2018 Jan;59(1):147-153
pubmed: 28705916
Curr Treat Options Oncol. 2000 Oct;1(4):359-67
pubmed: 12057161
J Nucl Med. 2009 Nov;50(11):1820-7
pubmed: 19837767
Eur J Nucl Med Mol Imaging. 2007 Oct;34(10):1617-26
pubmed: 17520251
Eur J Nucl Med Mol Imaging. 2003 May;30(5):781-93
pubmed: 12707737
Endocr Relat Cancer. 2017 Jun;24(6):R203-R221
pubmed: 28400403
Eur J Nucl Med. 1993 Aug;20(8):716-31
pubmed: 8404961
Theranostics. 2017 Mar 1;7(5):1149-1158
pubmed: 28435454
Pharmaceuticals (Basel). 2017 Mar 15;10(1):
pubmed: 28295000
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):176-85
pubmed: 25209134
J Nucl Med. 2021 Jul;62(Suppl 2):44S-50S
pubmed: 34230073
N Engl J Med. 2018 Dec 6;379(23):2220-2229
pubmed: 30280641
Eur J Nucl Med Mol Imaging. 2006 Nov;33(11):1273-9
pubmed: 16832634
EJNMMI Res. 2018 Jul 21;8(1):64
pubmed: 30032450
Endokrynol Pol. 2016;67(1):68-71
pubmed: 26884118
J Nucl Med. 2011 Jul;52(7):1073-8
pubmed: 21680696
Neuroendocrinology. 2012;96(4):261-71
pubmed: 22907438
Neuroendocrinology. 2017 Mar 30;105(3):212-244
pubmed: 28355596
Clin Nucl Med. 2019 Dec;44(12):978-980
pubmed: 31689280
Curr Oncol Rep. 2017 Feb;19(2):9
pubmed: 28220446
J Natl Compr Canc Netw. 2018 Jun;16(6):782-790
pubmed: 29891528
Endocr Rev. 2022 Mar 9;43(2):199-239
pubmed: 34147030
Surg Oncol. 2012 Sep;21(3):e131-41
pubmed: 22658833
Clin Case Rep. 2018 Mar 01;6(4):719-722
pubmed: 29636947
J Nucl Med. 2021 Jul;62(Suppl 2):51S-56S
pubmed: 34230074
J Nucl Med. 2022 Feb;63(2):218-225
pubmed: 34049983
J Nucl Med. 2000 Apr;41(4):636-42
pubmed: 10768564
J Nucl Med. 2020 Nov;61(11):1560-1569
pubmed: 32169914
J Clin Oncol. 2009 Oct 1;27(28):4656-63
pubmed: 19704057
Cancer. 2008 Jun;112(11):2447-55
pubmed: 18383518
Oncotarget. 2016 Apr 12;7(15):20033-40
pubmed: 26936994